Ultragenyx Price Targets Climb to $60, Signaling 155% Upside with UX111 Resubmission
H.C. Wainwright set a $60 price target on Ultragenyx, implying 155% upside, while Barclays assigned an Overweight rating with a $44 target for 87% upside potential. The bullish stance reflects an on-schedule BLA resubmission for UX111 in Sanfilippo syndrome type A and projected profitability by 2027.
1. Analyst Price Targets and Ratings
On February 3, H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Ultragenyx, setting a $60 price target for 155% potential upside, while Barclays assigned an Overweight rating on January 28 with a $44 target implying 87% upside.
2. UX111 BLA Resubmission Details
The company’s on-schedule BLA resubmission for UX111 covers Sanfilippo syndrome type A and includes extended neurologic efficacy data, biomarker improvements and an adequate safety profile for a disease without approved therapies.
3. Profitability and Financial Outlook
Ultragenyx is currently experiencing elevated cash burn as it advances its rare disease pipeline and remains on track to achieve profitability by 2027, reflecting its attractive long-term risk-reward profile.
4. Company Focus and Strategy
Specializing in novel therapies for rare and ultra-rare genetic diseases, Ultragenyx emphasizes gene therapy across multiple clinical stages to identify, acquire and commercialize treatments for underserved patient populations.